Dexcom: Stelo Rollout and Record Margins Ignite Price Momentum
Reading Time: 3 minutes
The successful introduction of the over-the-counter Stelo system opens up massive new patient groups for Dexcom beyond insulin dependency. A significant trading volume above the 100-day average confirms institutional investors' confidence in the new growth phase. Aspiring mid-term targets and a share buyback program underpin the growth story! DexCom is considered a global pioneer in continuous glucose monitoring (CGM). Dexcom develops highly precise sensors that measure blood sugar levels in real time and transmit the data directly to...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
